Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio

Authors
Cooper Mark
Perkovic Vlado
von Eynatten Maximilian
Marx Nikolaus
McGuire Darren
Woerle Hans-Juergen
Broedl Uli
George Jyothis
Rosenstock Julio
Wanner Christoph
Alexander John
Pencina Michael
Toto Robert
Zinman Bernard
Baanstra David
Pfarr Egon
Mattheus Michaela
CARMELINA® investigators
Type of Publication
Journal Article
Year of Publication
2018
Journal
Cardiovasc Diabetol
DOI
10.1186/s12933-018-0682-3
Language
Eng
ISSN Number
1475-2840
Volume
17
Issue
1
Number of Pages
39